Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Valproic acid-ethosuximide interaction: a pharmacokinetic study.

F Pisani, M C Narbone, C Trunfio

    Epilepsia
    |April 1, 1984
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    First Measurement of Time-Dependent CP Violation in the Flavor-Changing Neutral-Current Decay B^{0}→K_{S}^{0}μ^{+}μ^{-}.

    Physical review letters·2026
    Same author

    Measurement of the Top-Quark Production Cross Section and Charge Asymmetry at LHCb.

    Physical review letters·2026
    Same author

    Searches for B^{0}→K^{+}π^{-}τ^{+}τ^{-} and B_{s}^{0}→K^{+}K^{-}τ^{+}τ^{-} Decays.

    Physical review letters·2026
    Same author

    First Evidence of the B_{s}^{0}→K^{-}π^{+}γ Decay.

    Physical review letters·2026
    Same author

    Precision Measurement of CP Violation and Branching Fractions in B^{±}→K_{S}^{0}h^{±} (h=π, K) Decays and Search for the Rare Decay B_{c}^{±}→K_{S}^{0}K^{±}.

    Physical review letters·2026
    Same author

    First Observation of the B[over ¯]_{s}^{0}→Λ_{c}^{+}Λ[over ¯]_{c}^{-} Decay and Evidence for the B[over ¯]^{0}→Λ_{c}^{+}Λ[over ¯]_{c}^{-} Decay.

    Physical review letters·2026

    Valproic acid (VPA) may inhibit the metabolism of ethosuximide (ESM) in humans. This drug interaction study found increased ESM half-life and decreased clearance when co-administered with VPA.

    Area of Science:

    • Pharmacokinetics
    • Drug Interactions
    • Clinical Pharmacology

    Background:

    • Valproic acid (VPA) and ethosuximide (ESM) are commonly used antiepileptic drugs.
    • Understanding potential drug interactions is crucial for optimizing patient therapy.
    • Limited human data exists on the pharmacokinetic interaction between VPA and ESM.

    Purpose of the Study:

    • To investigate the pharmacokinetic interaction between valproic acid (VPA) and ethosuximide (ESM) in healthy human volunteers.
    • To determine if VPA affects the absorption, distribution, metabolism, or excretion of ESM.

    Main Methods:

    • A pharmacokinetic study involving six healthy drug-free volunteers (4 males, 2 females, aged 18-42).
    • Volunteers received a single oral dose of 500 mg ESM before and during VPA treatment (800-1600 mg/day).

    Related Experiment Videos

  • Blood samples were analyzed to determine ESM and VPA serum concentrations over time.

    • Main Results:

    • Co-administration of VPA with ESM resulted in a significant increase in ESM serum half-life (44 to 54 h, p<0.05).
    • Total body clearance of ESM significantly decreased (11.2 to 9.5 ml/min, p<0.05) during VPA treatment.
    • Serum VPA levels ranged from 66.8 to 95 µg/ml; other pharmacokinetic parameters remained unchanged.
    • Two subjects did not exhibit evidence of interaction, indicating interindividual variability.

    Conclusions:

    • Valproic acid (VPA) significantly inhibits the metabolism of ethosuximide (ESM) in humans.
    • This interaction can lead to altered ESM pharmacokinetics, potentially affecting therapeutic efficacy and safety.
    • Further research is warranted to explore factors influencing the variability of this VPA-ESM interaction.